CAR T-Cell Therapy Showed Long-Term Myeloma Benefits
Patients with fewer prior treatments experienced improved survival rates, as federal regulators updated safety guidelines.
Updated on Oct. 12, 2026 in Cancer
Long-term data from the CARTITUDE-2 clinical trial indicated that 54.2% of multiple myeloma patients remained progression-free five years after receiving CAR T-cell therapy. The findings offer new insight for patients considering this treatment in earlier lines of therapy.
Why it matters
Expanding access to CAR T-cell therapy is a major priority, as low referral rates currently prevent many eligible patients from receiving this treatment during early relapse. Easing restrictive safety requirements may help more patients navigate the logistics of these procedures.
In the CARTITUDE-2 cohort A trial, 20 evaluable patients with one to three prior lines of therapy showed a 69.2% overall survival rate at five years. The median follow-up for this study group was 60.7 months.
The players
Doris Hansen
A researcher at Moffitt Cancer Center who specializes in hematology and clinical trial outcomes for multiple myeloma.
FDA
The federal agency responsible for regulating the safety, efficacy, and clinical administration of cellular immunotherapies.
Moffitt Cancer Center
A research institution that conducts advanced clinical studies on hematologic malignancies and cellular therapies.
The details
CAR T-cell therapy involves collecting a patient's T-cells via apheresis and genetically modifying them to recognize and attack cancer cells after lymphodepletion. Because the process can cause significant side effects, the FDA previously mandated that patients remain near specialized centers for four weeks and avoid driving for eight weeks. Regulators have now reduced both of these required safety windows to two weeks to improve the patient experience.
Timeline
February 2022: FDA first approved cilta-cel for patients with at least four prior therapy lines.
October 12, 2026: Results presented by Doris Hansen.
Health Landscape
The CARTITUDE clinical trial program has fundamentally shifted how physicians approach multiple myeloma by evaluating cell-based interventions at earlier stages of disease. These long-term results signal a move toward integrating specialized immunotherapies before patients become heavily pretreated.
If you are managing multiple myeloma, these updated safety guidelines may reduce the time you and a caregiver need to spend away from home during treatment. Discuss the potential benefits and timing of CAR T-cell therapy with your oncologist to see if your specific treatment history aligns with these evolving options.
The takeaway
CAR T-cell therapy can offer durable, long-term progression-free survival for multiple myeloma patients who receive treatment earlier in their disease journey. Review your current treatment plan with your physician to understand if and when specialized immunotherapies become a viable next step.
Further reading
Learn more about the latest research and clinical updates in Cancer.
